<DOC>
	<DOCNO>NCT00585546</DOCNO>
	<brief_summary>The purpose study evaluate whether patient chronic heart failure due coronary artery disease require use leave ventricular assist device ( LVAD ) refractory heart failure recover sufficient heart function allow pump explanted . The study aim avoid need transplantation patient use standard heart failure medication reduce size leave ventricle use investigational drug , clenbuterol , improve leave ventricular function .</brief_summary>
	<brief_title>Harefield Recovery Protocol Study Patients With Refractory Chronic Heart Failure</brief_title>
	<detailed_description>The hypothesis study patient dilate nonischemic cardiomyopathy require support implant leave ventricular assist device ( LVAD ) chronic refractory heart failure , specific two-staged medical regimen design enhance maximal reverse remodeling ( angiotensin convert enzyme inhibitor , beta blocker , angiotensin receptor blocker , aldosterone antagonist digoxin [ stage 1 ] ) prevent/reverse myocardial atrophy ( β2 agonist clenbuterol [ stage 2 ] ) , recover adequate left ventricular systolic function allow LVAD explantation subsequent intermediate-term survival without need mechanical circulatory support heart transplantation . Within one year study 's start , new LVAD become standard care implantation , study device become inferior standard care shortly thereafter . By 2012 trial stop futility enrollment . Thus , certain original outcome delete , specifically single subject explanted , multivariate analysis sustainability reverse remodel follow LVAD explantation predictor recovery leave ventricular function/remodeling LVAD removal could do . Similarly , lack funding , biobank component collect ; therefore data exists present biochemical , structural , cellular molecular change myocardium result HARPS protocol intervention , change systemic inflammation , circulate progenitor cell growth factor , DEXA scan base data : change body mass , lean muscle mass , muscle strength maximal submaximal exercise capacity . All remain outcome measure edit precisely show outcome measure intend .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Cardiomyopathy , Dilated</mesh_term>
	<mesh_term>Clenbuterol</mesh_term>
	<criteria>Patients refractory symptomatic heart failure ( NYHA Class IV , Stage D ) due dilate , nonischemic cardiomyopathy meet follow criterion : Severe clinical heart failure associate haemodynamic compromise resistant intensive medical therapy require LVAD implantation Duration heart failure symptom ≥ 12 month prior LVAD implant Documentation LVEF ≤ 40 % least 1 year prior LVAD implantation LVEF ≤ 30 % cardiomegaly time LVAD implantation document radionuclide contrast ventriculography echocardiography Nonischemic etiology confirm coronary angiography within two year enrollment Listed heart transplantation plan list heart transplantation pending successful LVAD implantation one participating center , per usual transplant listing policy participate center &gt; = 18 year age Body surface area &gt; = 1.5 m2 Have implantable defibrillator place commitment implant ICD prior hospital discharge Have undergo insertion within prior 2 week insert Heartmate XVE LVAD use antimicrobial prophylaxis drive line restrain belt Not heart transplant candidate Evidence active acute myocarditis Pulmonary Vascular Resistance &gt; 6 Wood Units History previous CVA result significant fix motor deficit limit ability perform exercise test Previous prosthetic replacement aortic and/or mitral valve ( ) Hypertrophic obstructive cardiomyopathy LVIDD &lt; 5 cm surface echocardiogram ( restrictive cardiomyopathy ) Irreversible multiorgan failure Underlying bleed disorder , platelet count &lt; 75,000 , INR &gt; 2.5 ( without Coumadin ) , Hgb &lt; 8.0 . Pregnant lactate woman unwilling utilize two reliable method birth control woman childbearing age Receipt investigational drug therapy LVAD support</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>heart failure</keyword>
	<keyword>dilate cardiomyopathy</keyword>
	<keyword>heart assist device</keyword>
	<keyword>clenbuterol</keyword>
	<keyword>adrenergic beta agonist</keyword>
	<keyword>heart transplantation</keyword>
</DOC>